Clinical Trial Detail

NCT ID NCT02252263
Title A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors Bristol-Myers Squibb
Indications

multiple myeloma

Therapies

Urelumab

Lirilumab

Elotuzumab

Age Groups: adult

No variant requirements are available.